瑞士輝凌制藥Ferring Pharmaceuticals www.ferring.com
輝凌集團于1950年由Frederik Paulsen博士創(chuàng)辦，是世界上首家生產(chǎn)人工合成肽的公司之一, 并在不同的治療領(lǐng)域上，包括泌尿科、生殖醫(yī)學(xué)、婦產(chǎn)科、胃腸道疾病和內(nèi)分泌系統(tǒng)疾病等，開發(fā)各類創(chuàng)新藥品。
輝凌集團的總部設(shè)于瑞士，在瑞士、瑞典、丹麥、德國和捷克共和國均設(shè)有生產(chǎn)廠房，研發(fā)中心則在英國和美國，分支機構(gòu)遍布世界40多個國家。過去的20年間，輝凌集團保持每年約20%的增長。
于九十年代初，F(xiàn)ERRING在香港成立輝凌制藥有限公司，作為亞太區(qū)總部。在這十數(shù)年，成功將產(chǎn)品引進亞洲區(qū)內(nèi)多主要市場，令更多的病人獲得最新及最適當?shù)乃幬镏委煛?br /> 輝凌中國于1996年成立， 令輝凌集團成為其中一家最早獲準在國內(nèi)設(shè)立全資擁有企業(yè)的外國公司。為配合輝凌集團的發(fā)展計劃，輝凌中國于2003年在廣東省中山港國家健康基地興建了一所占地20,000平方尺的高科技生產(chǎn)廠房，總投資額為一千四百伍拾萬美元，廠房于2005年3月開幕后，成為輝凌集團在亞太區(qū)第一家生產(chǎn)廠房。
一直以來，F(xiàn)ERRING與很多大學(xué)、醫(yī)療機構(gòu)和其他研究所都有著緊密聯(lián)系，共同進行研究工作。我們深信，以我們?nèi)諠u擴展的網(wǎng)絡(luò)，F(xiàn)ERRING的產(chǎn)品將令更多病人受惠，從而實現(xiàn)我們的承諾：輝凌制藥 — 以科學(xué)造福人類。

總部位于瑞士的Ferring醫(yī)藥在全球范圍內(nèi)設(shè)銷售和生產(chǎn)點，在哥本哈根還有一個大型研發(fā)中心。全球有超過2700名員工，并以縮氨酸產(chǎn)品聞名于世。 

輝凌醫(yī)藥咨詢（上海）有限公司
上海市浦東新區(qū)源深路1088號 
葛洲壩大廈10樓01-03單元 
郵政編碼：200122
電話：021-38529666
傳真：021-38529661
電子郵件：info.china@ferring.com
北京咨詢分公司
北京市東城區(qū)建國門內(nèi)28號
民生金融中心A座11層03室
電話：010- 85295326
傳真：010- 85295336
電子郵件：info.china@ferring.com
北京發(fā)展中心
北京市東城區(qū)建國門內(nèi)28號
民生金融中心A座11層03室
電話：（86）10 8529-5338
傳真：（86）10 8529-5335
電子郵件：info.china@ferring.com
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of infertility, obstetrics, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ more than 3500 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, Israel and California, USA.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.